Johnson & Johnson (JNJ)'s Carvykti Sales Skyrocket 100% Amid Specialty Medicine Growth

We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Johnson & Johnson is placed second among them.

Johnson & Johnson (NYSE:JNJ), a global leader in pharmaceuticals, medical devices, and consumer health, continues to drive growth in 2025 through strategic investments in innovation and domestic manufacturing. The company is focused on expanding U.S. production capabilities to strengthen supply resilience, highlighted by a $2 billion investment in a state-of-the-art North Carolina facility. This expansion, part of a broader $55 billion U.S. manufacturing initiative over the next four years, includes a decade-long partnership with Fujifilm Diosynth and plans for additional sites nationwide.

On the pharmaceutical front, Johnson & Johnson (NYSE:JNJ)’s Innovative Medicine segment is performing strongly, with notable growth in key therapies such as Darzalex, Carvykti, and Tecvayli. Carvykti, a next-generation cell therapy for multiple myeloma, recorded over 100% sales growth in Q2 2025, helping offset the impact of the loss of exclusivity for Stelara. The business’s robust pipeline and operational success underscore its continued leadership in specialty medicines.

In medical devices, Johnson & Johnson (NYSE:JNJ) is advancing innovation with the launch of the VIRTUGUIDE™ AI-powered system, designed to improve efficiency and precision in orthopedic surgeries. This move highlights the firm’s commitment to integrating advanced technology into surgical care, benefiting both surgeons and patients.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.